Short Interest in Aytu BioPharma, Inc. (NASDAQ:AYTU) Grows By 7.1%

Aytu BioPharma, Inc. (NASDAQ:AYTU) saw a large increase in short interest in December. As of December 15th, there was short interest totalling 126,800 shares, an increase of 7.1% from the November 30th total of 118,400 shares. Currently, 2.1% of the shares of the stock are sold short. Based on an average daily volume of 37,000 shares, the short-interest ratio is currently 3.4 days.

Aytu BioPharma Price Performance

Shares of NASDAQ AYTU traded up $0.09 during midday trading on Tuesday, reaching $1.70. The company’s stock had a trading volume of 18,880 shares, compared to its average volume of 23,966. Aytu BioPharma has a one year low of $1.30 and a one year high of $3.45. The company has a market cap of $10.45 million, a price-to-earnings ratio of -1.38 and a beta of -1.40. The company has a 50 day moving average price of $1.67 and a 200 day moving average price of $2.26. The company has a current ratio of 0.99, a quick ratio of 0.80 and a debt-to-equity ratio of 0.35.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its holdings in shares of Aytu BioPharma by 54.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 23,551 shares of the company’s stock worth $69,000 after acquiring an additional 8,311 shares during the last quarter. Armistice Capital LLC acquired a new stake in Aytu BioPharma during the 2nd quarter worth about $736,000. Finally, Stonepine Capital Management LLC lifted its stake in Aytu BioPharma by 6.0% during the third quarter. Stonepine Capital Management LLC now owns 500,958 shares of the company’s stock valued at $1,177,000 after buying an additional 28,489 shares in the last quarter. Institutional investors own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.